The emerging role of 18F-fluorodeoxyglucose positron emission tomography in the management of primary and recurrent rectal cancer.
Chessin
David B
DB
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Kiran
Ravi P
RP
Akhurst
Timothy
T
Guillem
Jose G
JG
D002272:Carcinoembryonic Antigen / Q000097:blood; D003131:Combined Modality Therapy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D012004:Rectal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D012008:Recurrence; D014057:Tomography, X-Ray Computed
D002272:Carcinoembryonic Antigen; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18